Trials
6 active
34 in total · 8 in the EU
What this is
- How it works
- PCSK9 inhibitor (oral macrocyclic peptide)
- Tested for
- Hypercholesterolemia (2 trials), Hyperlipidemia, Arteriosclerosis, Hypercholesterolaemia, Heterozygous Familial Hypercholesterolemia (HeFH), Lipoprotein(a)
- Main trialPhase 3
- “Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.”In the company’s words, NCT07821944 on ClinicalTrials.gov
- Other names
- MK-0616 · Lipfendra
Other drugs for Hypercholesterolemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- LerodalcibepLIB Therapeutics LLC · Phase 3
Coming up6
- 14 DecPhase 1 trial completes · ClinicalTrials.gov
- 12 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 13 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- 29 Nov 2029Phase 3 trial completes · ClinicalTrials.gov
- 4 Dec 2033Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT07216482
Trials34
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 26 Nov 2027 | A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | |
| Phase 3Active, not recruiting | 13 Oct 2028 | Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension | |
| Phase 3Active, not recruiting | 29 Nov 2029 | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes | |
| Phase 2/3Recruiting | 4 Dec 2033 | A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) | |
| Phase 2Recruiting | 12 Oct 2027 | A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | |
| Phase 1Active, not recruiting | 14 Dec 2026 | A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) | |
| Phase 3Completed | 14 Feb 2025 | A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) | |
| Phase 3Completed | 7 Apr 2025 | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) | |
| Phase 3Completed | 28 Jul 2025 | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids | |
| Phase 3Completed | 3 Aug 2026 | A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | |
| Phase 2Completed | 28 Nov 2022 | A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) | |
| Phase 1Completed | 29 Dec 2022 | A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) | |
| Phase 1Completed | 3 May 2023 | A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007) | |
| Phase 1Completed | 8 May 2023 | A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010) | |
| Phase 1Completed | 2 Aug 2023 | A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016) | |
| Phase 1Completed | 26 Dec 2023 | The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022) | |
| Phase 1Completed | 29 Dec 2023 | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024) | |
| Phase 1Completed | 2 Jan 2024 | A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) | |
| Phase 1Completed | 19 Jan 2024 | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) | |
| Phase 1Completed | 1 May 2024 | A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) | |
| Phase 1Completed | 24 May 2024 | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | |
| Phase 1Completed | 4 Jun 2024 | A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026) | |
| Phase 1Completed | 21 Jun 2024 | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) | |
| Phase 1Completed | 19 Aug 2024 | A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) | |
| Phase 1Completed | 1 Nov 2024 | A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031) | |
| Phase 1Completed | 13 Jan 2025 | A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033) | |
| Phase 1Completed | 27 Jan 2025 | A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034) | |
| Phase 1Completed | 1 May 2025 | A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) | |
| Phase 1Completed | 16 May 2025 | A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) | |
| Phase 1Completed | 25 Jun 2025 | A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) | |
| Phase 1Completed | 13 Aug 2025 | A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) | |
| Phase 1Completed | 18 May 2026 | A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041) | |
| Phase 1Completed | 5 Sep 2026 | A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003) | |
| Phase 1Completed | 14 Oct 2026 | A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026